[go: up one dir, main page]

WO2011028195A3 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides - Google Patents

Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Download PDF

Info

Publication number
WO2011028195A3
WO2011028195A3 PCT/US2007/088009 US2007088009W WO2011028195A3 WO 2011028195 A3 WO2011028195 A3 WO 2011028195A3 US 2007088009 W US2007088009 W US 2007088009W WO 2011028195 A3 WO2011028195 A3 WO 2011028195A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural amino
polypeptides
amino acids
amino acid
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/088009
Other languages
French (fr)
Other versions
WO2011028195A2 (en
Inventor
Zhenwei Miao
Junjie Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Anticipated expiration legal-status Critical
Publication of WO2011028195A2 publication Critical patent/WO2011028195A2/en
Publication of WO2011028195A3 publication Critical patent/WO2011028195A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, but typically have at least one indole, carbonyl, and/or hydrazine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one indole, carbonyl, and/or hydrazine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.
PCT/US2007/088009 2006-12-18 2007-12-18 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Ceased WO2011028195A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87059406P 2006-12-18 2006-12-18
US60/870,594 2006-12-18

Publications (2)

Publication Number Publication Date
WO2011028195A2 WO2011028195A2 (en) 2011-03-10
WO2011028195A3 true WO2011028195A3 (en) 2011-06-16

Family

ID=39536734

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/088011 Ceased WO2008077079A1 (en) 2006-12-18 2007-12-18 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
PCT/US2007/088009 Ceased WO2011028195A2 (en) 2006-12-18 2007-12-18 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088011 Ceased WO2008077079A1 (en) 2006-12-18 2007-12-18 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Country Status (8)

Country Link
EP (1) EP2079687A1 (en)
JP (1) JP2010512800A (en)
KR (1) KR20090100407A (en)
CN (1) CN101578264A (en)
AU (1) AU2007333737A1 (en)
CA (1) CA2672205A1 (en)
MX (1) MX2009006617A (en)
WO (2) WO2008077079A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637306B2 (en) * 2008-12-10 2014-01-28 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SI2605789T1 (en) * 2010-08-17 2019-10-30 Ambrx Inc Modified relaxin polypeptides and their uses
KR20140016262A (en) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
US20150018530A1 (en) * 2012-02-29 2015-01-15 Ambrx, Inc. Novel Prodrug Containing Molecule Compositions and Their Uses
WO2013130917A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-3 polypeptide conjugates their uses
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2725329T3 (en) * 2012-06-07 2019-09-23 Ambrx Inc Prostate specific membrane antigen antibody drug conjugates
AU2013277169B2 (en) * 2012-06-19 2017-02-02 Ambrx, Inc. Anti-CD70 antibody drug conjugates
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
JP6064062B2 (en) 2013-03-15 2017-01-18 ファイザー・インク Indazole compounds that activate AMPK
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
CN109069635B (en) 2016-02-04 2023-09-26 斯克利普斯研究所 Humanized anti-CD3 antibodies, conjugates and uses thereof
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
PE20191716A1 (en) 2017-02-08 2019-12-05 Bristol Myers Squibb Co MODIFIED RELAXIN POLYPEPTIDES INCLUDING A PHARMACOKINETIC ENHANCER AND THEIR USES
WO2019241430A2 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
HUE065882T2 (en) 2018-09-11 2024-06-28 Ambrx Inc Interleukin-2-polypeptide conjugates and their applications
CA3131391A1 (en) 2019-02-27 2020-09-03 Angiex, Inc. Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
CN114127974B (en) * 2019-05-13 2023-04-18 上海宸安生物科技有限公司 Markers for labeling biomolecules
CN114524934B (en) * 2020-11-23 2024-01-30 华东理工大学 Application of polypeptide polymer or polypeptide mimic in bone repair
EP4368722A4 (en) * 2021-07-07 2025-11-26 Ajinomoto Kk Method for secretory production of unnatural-amino-acid-containing protein
EP4598586A1 (en) 2022-10-07 2025-08-13 Ambrx, Inc. Drug linkers and antibody conjugates thereof
CN120882432A (en) 2023-01-16 2025-10-31 Ambrx 公司 Anti-CD 70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
AR131133A1 (en) 2023-05-24 2025-02-19 Ambrx Inc PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOF
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052539A1 (en) * 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US6858577B1 (en) * 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
EP1291341A4 (en) * 2000-05-30 2005-04-27 Chugai Pharmaceutical Co Ltd COMPOUNDS WITH THROMBOPOIETINIC EFFECT
JP4623962B2 (en) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052539A1 (en) * 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARLIER, PAUL R. ET AL.: "Catalytic Asymmetric Synthesis of Protected Tryptophan Regioisomers.", JOURNAL OF ORGANIC CHEMISTRY, vol. 67, 2002, pages 6256 - 6259 *
FAUQ, ABDUL H. ET AL.: "Synthesis of (25)-2-amino-3-(lH-4-indolyl)propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides.", TETRAHEDRON: ASYMMETRY, vol. 9, 1998, pages 4127 - 4134 *
TROXLER, FRANZ.: "Synthetic indole compounds. IV. Preparative Application of Mannich Bases of Hydroxyindoles as Alkylation agents.", HELVETICA CHIMICA ACTA, vol. 51, 1968, pages 1214 - 1224 *

Also Published As

Publication number Publication date
JP2010512800A (en) 2010-04-30
WO2008077079A1 (en) 2008-06-26
KR20090100407A (en) 2009-09-23
CN101578264A (en) 2009-11-11
MX2009006617A (en) 2009-07-24
WO2011028195A2 (en) 2011-03-10
AU2007333737A1 (en) 2008-06-26
CA2672205A1 (en) 2008-06-26
EP2079687A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
WO2011028195A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007070659A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2006069246A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP3470413A3 (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX2020001231A (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives.
MX2009007001A (en) Phenazine and quinoxaline substituted amino acids and polypeptides.
NZ778565A (en) Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2007076032A3 (en) Compositions and methods for producing a composition
WO2007130453A3 (en) Non-natural amino acid substituted polypeptides
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2011036445A3 (en) Polypeptides and uses thereof
EP4245766A3 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2007021494A3 (en) Albumin fusion proteins
EP2455462A3 (en) Lipase variants for pharmaceutical use
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2006062685A3 (en) Novel peptides that bind to the erythropoietin receptor
WO2007075438A3 (en) Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2008046232A8 (en) Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
EP2803674A3 (en) Antibody recognizing C-domain of midkine
WO2006060148A3 (en) Novel peptides that bind to the erythropoietin receptor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07875284

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 07875284

Country of ref document: EP

Kind code of ref document: A1